LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple
LB Pharma is testing a new medicine for schizophrenia and now expects to share their results in the first half of 2027, then talk to the FDA later that year about approval. When a company moves forward with medicine testing on schedule, it shows they're making progress—but remember, we won't know if it actually works until those results come out.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.